Edition:
United States

Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

4.77USD
4:00pm EDT
Change (% chg)

$-0.12 (-2.45%)
Prev Close
$4.89
Open
$4.87
Day's High
$4.88
Day's Low
$4.66
Volume
73,548
Avg. Vol
101,513
52-wk High
$7.67
52-wk Low
$3.68

Chart for

About

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical... (more)

Overall

Beta: 2.84
Market Cap(Mil.): $233.45
Shares Outstanding(Mil.): 47.16
Dividend: --
Yield (%): --

Financials

  PETX.OQ Industry Sector
P/E (TTM): -- 29.92 34.14
EPS (TTM): -1.03 -- --
ROI: -40.69 13.64 13.17
ROE: -49.18 15.43 15.14

BRIEF-Aratana Appoints Craig Barbarosh And Lowell Robinson To Board In Cooperation Agreement With Engaged Capital

* ARATANA THERAPEUTICS APPOINTS CRAIG BARBAROSH AND LOWELL ROBINSON TO ITS BOARD OF DIRECTORS IN COOPERATION AGREEMENT WITH ENGAGED CAPITAL

May 21 2018

BRIEF-Aratana Therapeutics Q1 Loss Per Share $0.19

* ARATANA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 03 2018

BRIEF-Engaged Capital Reports 5.2 Pct Stake In Aratana Therapeutics Inc, As Of April 4, 2018 SEC Filing

* ENGAGED CAPITAL LLC SAYS PURCHASED ARATANA THERAPEUTICS' SHARES BASED ON BELIEF THAT THE SHARES, WHEN PURCHASED, WERE UNDERVALUED

Apr 05 2018

BRIEF-Aratana Therapeutics Reports Q4 Loss Per Share $0.37

* ARATANA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 13 2018

BRIEF-Aratana Therapeutics Expands Therapeutic Candidate Pipeline

* ARATANA THERAPEUTICS EXPANDS THERAPEUTIC CANDIDATE PIPELINE

Mar 01 2018

BRIEF-Elanco, Aratana Announce Marketing Authorization Of Galliprant In Europe

* ELANCO, ARATANA ANNOUNCE MARKETING AUTHORIZATION OF GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE Source text for Eikon: Further company coverage:

Jan 11 2018

BRIEF-Aratana Therapeutics Granted Conditional License For A Canine Osteosarcoma Therapeutic

* ARATANA THERAPEUTICS GRANTED CONDITIONAL LICENSE FOR A CANINE OSTEOSARCOMA THERAPEUTIC

Dec 20 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF75.60 +0.10
Merck & Co., Inc. (MRK.N) $61.03 +0.04
Bayer AG (BAYGn.DE) €96.63 -1.83
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €67.67 -0.58
Eli Lilly And Co (LLY.N) $86.82 +0.71
Zoetis Inc (ZTS.N) $87.25 -1.68
Virbac SA (VIRB.PA) €119.80 -2.00
Vetoquinol SA (VETO.PA) €50.20 -1.40
Dechra Pharmaceuticals plc (DPH.L) 2,718.00 -30.00

Earnings vs. Estimates